CPIX · Cumberland Pharmaceuticals Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings (loss) per share non-GAAP | -$0.39 | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted earnings (loss) and adjusted diluted earnings (loss) per share non-GAAP | -$5,836,504 | Six months ended June 30, 2026 | — |
| Adjusted loss non-GAAP | $1.9M | first quarter of 2026 | — |
| Adjusted Earnings non-GAAP | $1.7M | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CPIX
this stock
Cumberland Pharmaceuticals Inc
|
$114.62M | +92.2% | +16.7% | — | 2.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.06B | +16.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.91B | +3.3% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.98B | -1.1% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CPIX | -1.8% | +15.7% | +58.1% | +14.5% | +92.2% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -0.4% | +12.1% | +46.5% | +12.0% | +79.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.